Sigyn Therapeutics, Inc. (SIGY)
| Market Cap | 147.84K -95.2% |
| Revenue (ttm) | n/a |
| Net Income | -3.22M |
| EPS | -2.01 |
| Shares Out | 5.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,000 |
| Open | 0.0300 |
| Previous Close | 0.0304 |
| Day's Range | 0.0278 - 0.0303 |
| 52-Week Range | 0.0103 - 2.0000 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Sigyn Therapeutics
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sig... [Read more]
Financial Performance
Financial StatementsNews
Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX
Presentation on Tuesday, October 21st at 4:00 PM PT San Diego, California--(Newsfile Corp. - October 21, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to addre...
Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
RETRANSMISSION: Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Underfollowed Innovator to Enjoy Profile Raise BALTIMORE, MD / ACCESS Newswire / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sect...
Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Underfollowed Innovator to Enjoy Profile Raise BALTIMORE, MD / ACCESS Newswire / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sect...
Sigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor Conference
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
Sigyn Therapeutics™ to Present at Tomorrow's Emerging Growth Conference
Live Online Presentation Scheduled at 12 pm EST on March 6 th SAN DIEGO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OT...
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology c...
Sigyn Therapeutics Completes Reverse Stock Split
SAN DIEGO, CA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: “SIGYD”, “SIGY”), a development-stage medical technology company, disclos...
Sigyn Therapeutics announces 1-for-40 reverse stock split
Sigyn Therapeutics announced that a 1-for-40 reverse split of its common stock will be implemented tomorrow, January 31, 2024. As a result, the Company’s common stock will trade on a…
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced ...
Sigyn Therapeutics releases letter to shareholders
Sigyn Therapeutics announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce. “Over the past eighteen months, we set the stage for first-in-human studie...
Sigyn Therapeutics appoints Jerry DeCiccio as CFO
Sigyn Therapeutics announced the appointment of Jerry DeCiccio, CPA, MBA, as CFO. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications, and Pr...
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced ...
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces fi...
Sigyn Therapeutics reports PCT patent submission to enhance chemo delivery
Sigyn Therapeutics disclosed the submission of a Patent Cooperation Treaty application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY.” The PCT submission is associ...
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
SAN DIEGO, CA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today disclosed ...
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
SAN DIEGO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a medical technology company that creates blood purification devices to overcome cle...
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification devi...
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
SAN DIEGO, CA, May 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, disclosed today t...
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
SAN DIEGO, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces fi...
Sigyn Therapeutics announces appointment of Marleau as Chief Scientific Officer
Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, CSO, effective immediately. Dr. Marleau is a recognized thought leader in the development of therape...
Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company focused on the creation...
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
SAN DIEGO, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company that creates blood puri...
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solut...